drugset / Trial / NCT03519646
Eliglustat on Gaucher Disease Type IIIB
NaSingle-groupOpen-labelTreatment
Summary
Evaluation of the safety in the combination usage of Cerdelga and Cerezyme in type III Gaucher disease patients and the efficacy on soft tissue diseases.
Timeline
- Start
- 2018-04-23
- Primary completion
- 2020-09-11
- Completion
- 2020-09-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eliglustat | Small molecule | 21 mg | — |
| Subject | Eliglustat | Small molecule | 42 mg | — |
| Subject | Eliglustat | Small molecule | 84 mg | — |